Prognostic significance of p16/CDKN2A deletion in pleural mesotheliomas

被引：0
|
作者：
Dacic, S.
Poppei, H. H.
Kothmaier, H.
Halbwedt, I.
Morbini, P.
Murer, B.
Comin, C. E.
Galateau-Salle, F.
Demirag, F.
Zeren, H.
Allanoos, R.
Gibbs, A.
Cagle, P. T.
机构：
[1] Univ Pittsburgh, Pittsburgh, PA 15260 USA
[2] Inst Pathol, Graz, Austria
[3] Inst Pathol Anat, Pavia, Italy
[4] Osped Umberto 1, Venice, Italy
[5] Univ Florence, I-50121 Florence, Italy
[6] CHU Cote Nacre, Caen, France
[7] Ataturk Chest Dis Hosp, Ankara, Turkey
[8] Adana Univ, Adana, Turkey
[9] Llandough Hosp, Cardiff & Vale NHS Trust, Cardiff, Wales
[10] Methodist Hosp, Houston, TX USA
来源：
MODERN PATHOLOGY | 2008年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
1547
引用
收藏
页码：339A / 340A
页数：2
相关论文
共 50 条
  • [21] The CDKN2A (p16) Gene and Human Cancer
    William D. Foulkes
    Tamar Y. Flanders
    Pamela M. Pollock
    Nicholas K. Hayward
    Molecular Medicine, 1997, 3 : 5 - 20
  • [22] The CDKN2A (p16) gene and human cancer
    Foulkes, WD
    Flanders, TY
    Pollock, PM
    Hayward, NK
    MOLECULAR MEDICINE, 1997, 3 (01) : 5 - 20
  • [23] CDKN2A/p16 inactivation in the prognosis of oligodendrogliomas
    Bortolotto, S
    Chiadò-Piat, L
    Cavalla, P
    Bosone, I
    Chiò, A
    Mauro, A
    Schiffer, D
    INTERNATIONAL JOURNAL OF CANCER, 2000, 88 (04) : 554 - 557
  • [24] Clinicopathological Significance and Potential Drug Target of CDKN2A/p16 in Endometrial Carcinoma
    Su, Li
    Wang, Hanwei
    Miao, Jingwei
    Liang, Ying
    SCIENTIFIC REPORTS, 2015, 5
  • [25] Clinicopathological Significance and Potential Drug Target of CDKN2A/p16 in Endometrial Carcinoma
    Li Su
    Hanwei Wang
    Jingwei Miao
    Ying Liang
    Scientific Reports, 5
  • [26] CDKN2A and MTAP deletions in peritoneal mesotheliomas are correlated with loss of p16 protein expression and poor survival
    Krasinskas, Alyssa M.
    Bartlett, David L.
    Cieply, Kathleen
    Dacic, Sanja
    MODERN PATHOLOGY, 2010, 23 (04) : 531 - 538
  • [27] P16 immunohistochemistry is a sensitive and specific surrogate marker for CDKN2A homozygous deletion in gliomas
    Vij, Meenakshi
    Cho, Benjamin B. B.
    Yokoda, Raquel T. T.
    Rashidipour, Omid
    Umphlett, Melissa
    Richardson, Timothy E. E.
    Tsankova, Nadejda M. M.
    ACTA NEUROPATHOLOGICA COMMUNICATIONS, 2023, 11 (01)
  • [28] P16 immunohistochemistry is a sensitive and specific surrogate marker for CDKN2A homozygous deletion in gliomas
    Meenakshi Vij
    Benjamin B. Cho
    Raquel T. Yokoda
    Omid Rashidipour
    Melissa Umphlett
    Timothy E. Richardson
    Nadejda M. Tsankova
    Acta Neuropathologica Communications, 11
  • [29] Loss of p16 expression is a sensitive marker of CDKN2A homozygous deletion in malignant meningiomas
    Tang, Vivian
    Lu, Rufei
    Mirchia, Kanish
    Van Ziffle, Jessica
    Devine, Patrick
    Lee, Julieann
    Phillips, Joanna J. J.
    Perry, Arie
    Raleigh, David R. R.
    Lucas, Calixto-Hope G.
    Solomon, David A. A.
    ACTA NEUROPATHOLOGICA, 2023, 145 (04) : 497 - 500
  • [30] CDKN2A deletion in pediatric versus adult glioblastomas and predictive value of p16 immunohistochemistry
    Purkait, Suvendu
    Jha, Prerana
    Sharma, Mehar Chand
    Suri, Vaishali
    Sharma, Manish
    Kale, Shashank Sharad
    Sarkar, Chitra
    NEUROPATHOLOGY, 2013, 33 (04) : 405 - 412
12345